The pharmacokinetics and the pharmacodynamics of cannabinoids
There is increasing interest in the use of cannabinoids for disease and symptom
management, but limited information available regarding their pharmacokinetics and …
management, but limited information available regarding their pharmacokinetics and …
Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
EB Russo - British journal of pharmacology, 2011 - Wiley Online Library
Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964,
when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic …
when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic …
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …
Cannabidiol: State of the art and new challenges for therapeutic applications
Over the past years, several lines of evidence support a therapeutic potential of Cannabis
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …
Pharmacokinetics and pharmacodynamics of cannabinoids
F Grotenhermen - Clinical pharmacokinetics, 2003 - Springer
Abstract Δ 9-Tetrahydrocannabinol (THC) is the main source of the pharmacological effects
caused by the consumption of cannabis, both the marijuana-like action and the medicinal …
caused by the consumption of cannabis, both the marijuana-like action and the medicinal …
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
S Burstein - Bioorganic & medicinal chemistry, 2015 - Elsevier
First isolated from Cannabis in 1940 by Roger Adams, the structure of CBD was not
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
(−)‐Cannabidiol (CBD) is a non‐psychotropic component of Cannabis with possible
therapeutic use as an anti‐inflammatory drug. Little is known on the possible molecular …
therapeutic use as an anti‐inflammatory drug. Little is known on the possible molecular …
[HTML][HTML] Human cannabinoid pharmacokinetics
MA Huestis - Chemistry & biodiversity, 2007 - ncbi.nlm.nih.gov
A multitude of roles for the endogenous cannabinoid system has been proposed by recent
research efforts. A large number of endogenous cannabinoid neurotransmitters or …
research efforts. A large number of endogenous cannabinoid neurotransmitters or …
Cannabinoid delivery systems for pain and inflammation treatment
There is a growing body of evidence to suggest that cannabinoids are beneficial for a range
of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms …
of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms …
[HTML][HTML] Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs
LJ Gamble, JM Boesch, CW Frye… - Frontiers in veterinary …, 2018 - frontiersin.org
Objectives The objectives of this study were to determine basic oral pharmacokinetics, and
assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with …
assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with …